AU2018358125B2 - Methods of oral immunotherapy - Google Patents

Methods of oral immunotherapy

Info

Publication number
AU2018358125B2
AU2018358125B2 AU2018358125A AU2018358125A AU2018358125B2 AU 2018358125 B2 AU2018358125 B2 AU 2018358125B2 AU 2018358125 A AU2018358125 A AU 2018358125A AU 2018358125 A AU2018358125 A AU 2018358125A AU 2018358125 B2 AU2018358125 B2 AU 2018358125B2
Authority
AU
Australia
Prior art keywords
peanut
subject
level
dose
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018358125A
Other languages
English (en)
Other versions
AU2018358125A1 (en
Inventor
Stephen G. Dilly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Publication of AU2018358125A1 publication Critical patent/AU2018358125A1/en
Assigned to SOCIETE DES PRODUITS NESTLE S.A. reassignment SOCIETE DES PRODUITS NESTLE S.A. Request for Assignment Assignors: AIMMUNE THERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2018358125B2 publication Critical patent/AU2018358125B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2018358125A 2017-11-02 2018-11-01 Methods of oral immunotherapy Active AU2018358125B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762580999P 2017-11-02 2017-11-02
US62/580,999 2017-11-02
US201862631406P 2018-02-15 2018-02-15
US62/631,406 2018-02-15
US201862637903P 2018-03-02 2018-03-02
US62/637,903 2018-03-02
US201862674478P 2018-05-21 2018-05-21
US62/674,478 2018-05-21
PCT/US2018/058777 WO2019089978A1 (en) 2017-11-02 2018-11-01 Methods of oral immunotherapy

Publications (2)

Publication Number Publication Date
AU2018358125A1 AU2018358125A1 (en) 2020-05-14
AU2018358125B2 true AU2018358125B2 (en) 2025-09-04

Family

ID=66332382

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018358125A Active AU2018358125B2 (en) 2017-11-02 2018-11-01 Methods of oral immunotherapy

Country Status (9)

Country Link
US (2) US11369676B2 (https=)
EP (1) EP3703743A4 (https=)
JP (1) JP7498661B2 (https=)
KR (1) KR102753602B1 (https=)
CN (1) CN111344010A (https=)
AU (1) AU2018358125B2 (https=)
CA (1) CA3080601A1 (https=)
MX (1) MX2020004683A (https=)
WO (1) WO2019089978A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
WO2014159607A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Manufacture of peanut formulations for oral desensitization
AU2015306683B2 (en) 2014-08-25 2021-11-25 Societe Des Produits Nestle S.A. Egg protein formulations and methods of manufacture thereof
EP4545077A1 (en) 2017-12-06 2025-04-30 Prollergy Corporation Composition and method for reducing allergic response
US11406563B2 (en) 2018-07-27 2022-08-09 Société des Produits Nestlé S.A. Oral immunotherapy unit dose dispensing systems and methods
WO2020037151A1 (en) 2018-08-16 2020-02-20 Aimmune Therapeutics, Inc. Peanut oral immunotherapy with maintenance dose
WO2020100024A1 (en) * 2018-11-12 2020-05-22 Murdoch Childrens Research Institute Method and system
CA3123605A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
EP3965815A4 (en) * 2019-05-10 2023-05-31 Société des Produits Nestlé S.A. METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT
CA3162040A1 (en) * 2019-12-23 2021-07-01 Bronwyn POLLOCK Pharmaceutical compositions
AU2020412960A1 (en) * 2019-12-23 2022-06-16 Prota Therapeutics Pty Ltd Allergy treatment
BR112022026945A2 (pt) 2020-07-01 2023-03-07 Nestle Sa Determinação de equipe médica para imunoterapia oral
WO2022089595A1 (en) * 2020-10-30 2022-05-05 Oneness Biotech Co., Ltd. Biomarkers for ige-mediated diseases
JP2024509087A (ja) * 2021-02-24 2024-02-29 オールアダプト イミュノセラピューティクス，インコーポレイテッド アレルギーの治療方法
US20250342925A1 (en) * 2022-04-15 2025-11-06 Samsung Life Public Welfare Foundation Method for providing food allergy treatment service using oral immunotherapy, computer program stored in recording medium to implement method, and system

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140093541A1 (en) * 2011-03-17 2014-04-03 Cambridge University Hospitals Nhs Foundation Treatment for peanut allergy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809767A (en) 1969-05-12 1974-05-07 Griffith Laboratories Methods of making vegetable protein concentrates
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
US7820175B2 (en) 2004-03-19 2010-10-26 Herbal Spring, Llc Herbal therapy for the treatment of food allergy
US20090111702A1 (en) 2004-04-06 2009-04-30 Mount Sinai School Of Medicine Office Of Industrial Liason Methods of determining allergen response using microarray immunoassay techniques
MX2011006353A (es) 2008-12-19 2011-07-13 Merz Pharma Gmbh & Co Kgaa Derivados de 1-amino-alquilciclohexano para el tratamiento de enfermedades mediadas por mastocitos.
UY33472A (es) 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
DE102011086048A1 (de) 2011-04-07 2012-10-11 Continental Teves Ag & Co. Ohg Gehäuseseitige Trennschicht zur Stressentkopplung von vergossenen Elektroniken
WO2014159607A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Manufacture of peanut formulations for oral desensitization
US9492535B2 (en) * 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
US20150320706A1 (en) * 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
AU2015306683B2 (en) 2014-08-25 2021-11-25 Societe Des Produits Nestle S.A. Egg protein formulations and methods of manufacture thereof
EP3568027A4 (en) 2017-01-13 2020-11-11 Aimmune Therapeutics, Inc. WALNUT FLOUR MANUFACTURING PROCESSES AND FORMULATIONS FOR ORAL IMMUNOTHERAPY

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140093541A1 (en) * 2011-03-17 2014-04-03 Cambridge University Hospitals Nhs Foundation Treatment for peanut allergy

Also Published As

Publication number Publication date
AU2018358125A1 (en) 2020-05-14
US20190167785A1 (en) 2019-06-06
CA3080601A1 (en) 2019-05-09
MX2020004683A (es) 2020-08-13
JP7498661B2 (ja) 2024-06-12
US11369676B2 (en) 2022-06-28
EP3703743A4 (en) 2021-12-08
CN111344010A (zh) 2020-06-26
EP3703743A1 (en) 2020-09-09
US12357688B2 (en) 2025-07-15
WO2019089978A1 (en) 2019-05-09
JP2021501763A (ja) 2021-01-21
KR20200083526A (ko) 2020-07-08
KR102753602B1 (ko) 2025-01-10
US20220288196A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
US12357688B2 (en) Methods of oral immunotherapy
JP7536035B2 (ja) ピーナツに対する経口免疫療法における全身性アレルギー応答リスク評価
Greenberger et al. Idiopathic anaphylaxis
JP2023011814A (ja) 糖尿病バイオマーカ
Porcaro et al. Anaphylaxis to cutaneous exposure to bovine colostrum based cream
JP7824217B2 (ja) アレルギー治療
Sicherer et al. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects
US20250011474A1 (en) ANTI-IgE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES
Chiewchalermsri et al. Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in the build-up phase of house dust mite-specific immunotherapy
Cheam et al. Immunoglobulin E-mediated reactions to corticosteroids
Kattan Oral food challenges in routine clinical practice
Epstein‐Rigbi et al. Decreased Severity of Oral Immunotherapy Induced Gastrointestinal Eosinophilic Reactions Following Revisions in Milk‐Treatment Protocol
Nagakura et al. Randomized Trial of Milk Oral Immunotherapy: Fixed Low-Dose vs Escalation to Medium-Dose
Li Immunological Humoral and Cellular Activation Profiles in the Low Dose Multi Allergen Oral Immunotherapy Trial
Zheng et al. Novel Diagnostic and Immunotherapeutic Approaches for Wheat Allergy
Cosper et al. 7 to 11: Food Allergy Treatment Therapies
Sankararaman et al. Food Intolerances and IgE-Mediated Food Allergies
EP4110364A1 (en) Methods for detecting food allergies
Averell et al. OBSERVATIONAL VIGNETTE STUDY TO EXAMINE PATIENT, HEALTHCARE PROVIDER, AND CAREGIVER PERCEIVED BURDEN OF ASTHMA-RELATED EXACERBATIONS
Schussler et al. Penicillin skin testing is a safe and effective tool for evaluating penicillin allergy in the pediatric population
Bermejo et al. Effectiveness and Adverse Effects of Azathioprine in Inflammatory Bowel Disease: 5-Year Follow-up Study
Deppe et al. Washing feather and synthetic pillows.
Bilò et al. From Immunotherapy
GÜLEN Venom-immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection
SIMPSON et al. British Society for Allergy and Clinical Immunology 18th–20th July 2005

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SOCIETE DES PRODUITS NESTLE S.A.

Free format text: FORMER APPLICANT(S): AIMMUNE THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)